anti-siglec-6 CAR-T cell therapy(Xuzhou Medical University)

N/A

Report date: 2022/08/08 20:00:25

Base Information

Drug Nameanti-siglec-6 CAR-T cell therapy(Xuzhou Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti Sialic acid-binding Ig-like lectin 6
TargetsSialic acid-binding Ig-like lectin 6
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesXuzhou Medical University (Xzmu)
China Registration ClassN/A

Develop Information

Active CompaniesXuzhou Medical University (Xzmu)
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A